JP2006502162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502162A5 JP2006502162A5 JP2004534462A JP2004534462A JP2006502162A5 JP 2006502162 A5 JP2006502162 A5 JP 2006502162A5 JP 2004534462 A JP2004534462 A JP 2004534462A JP 2004534462 A JP2004534462 A JP 2004534462A JP 2006502162 A5 JP2006502162 A5 JP 2006502162A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- pharmaceutical composition
- composition
- agent
- increase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000003577 HIV wasting syndrome Diseases 0.000 claims 1
- 206010020100 Hip fracture Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 230000003262 anti-osteoporosis Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 102000003998 progesterone receptors Human genes 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40809902P | 2002-09-04 | 2002-09-04 | |
| US49164503P | 2003-07-31 | 2003-07-31 | |
| PCT/US2003/027513 WO2004021984A2 (en) | 2002-09-04 | 2003-09-02 | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006502162A JP2006502162A (ja) | 2006-01-19 |
| JP2006502162A5 true JP2006502162A5 (enExample) | 2006-05-18 |
| JP4658600B2 JP4658600B2 (ja) | 2011-03-23 |
Family
ID=31981567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004534462A Expired - Lifetime JP4658600B2 (ja) | 2002-09-04 | 2003-09-02 | 成長ホルモン分泌促進剤として有用なヘテロ環状芳香族化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US7166596B2 (enExample) |
| EP (2) | EP1551511B1 (enExample) |
| JP (1) | JP4658600B2 (enExample) |
| KR (3) | KR20110003592A (enExample) |
| CN (2) | CN101863886A (enExample) |
| AR (1) | AR041143A1 (enExample) |
| AU (1) | AU2003270065B2 (enExample) |
| BR (1) | BR0314024A (enExample) |
| CA (1) | CA2496842C (enExample) |
| CY (2) | CY1120250T1 (enExample) |
| DK (2) | DK1551511T5 (enExample) |
| ES (2) | ES2706578T3 (enExample) |
| GE (1) | GEP20074019B (enExample) |
| HR (1) | HRP20050188B1 (enExample) |
| HU (2) | HUE041936T2 (enExample) |
| IL (5) | IL166802A (enExample) |
| IS (1) | IS7719A (enExample) |
| LT (2) | LT2570414T (enExample) |
| MX (1) | MXPA05002301A (enExample) |
| MY (1) | MY139563A (enExample) |
| NO (1) | NO332370B1 (enExample) |
| NZ (1) | NZ538166A (enExample) |
| PE (1) | PE20040997A1 (enExample) |
| PL (1) | PL219563B1 (enExample) |
| PT (2) | PT2570414T (enExample) |
| RS (2) | RS55124B1 (enExample) |
| RU (1) | RU2382042C2 (enExample) |
| SI (2) | SI2570414T1 (enExample) |
| TW (2) | TWI330185B (enExample) |
| WO (1) | WO2004021984A2 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| AR043443A1 (es) * | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1784390A2 (en) * | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
| CA2576915A1 (en) * | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CN101039942A (zh) * | 2004-09-27 | 2007-09-19 | 伊利舍医药品公司 | 磺酰胺类及其用途 |
| US8143425B2 (en) * | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CN101248042A (zh) * | 2005-06-10 | 2008-08-20 | 伊利舍医药品公司 | 磺酰胺类化合物及其用途 |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| RS55630B1 (sr) * | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
| JP5291471B2 (ja) * | 2006-02-15 | 2013-09-18 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| JP2009531390A (ja) * | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| AU2007272009A1 (en) * | 2006-07-12 | 2008-01-17 | Syngenta Limited | Triazolopyridine derivatives as herbicides |
| CA2670636A1 (en) | 2006-11-27 | 2008-06-05 | H. Lundbeck A/S | Heteroaryl amide derivatives |
| TW200835502A (en) * | 2006-12-26 | 2008-09-01 | Daiichi Sankyo Co Ltd | Thiazepine derivatives |
| ES2602789T3 (es) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| CN103204852A (zh) | 2007-04-10 | 2013-07-17 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
| US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
| US8242271B2 (en) * | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
| BRPI0816970A2 (pt) | 2007-09-14 | 2015-03-24 | Ortho Mcneil Janssen Pharm | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| CA2704436C (en) | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5535931B2 (ja) * | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| JP5775094B2 (ja) | 2009-12-29 | 2015-09-09 | イーライ リリー アンド カンパニー | 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物 |
| US8343977B2 (en) | 2009-12-30 | 2013-01-01 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| EP2446898A1 (en) * | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US20140287997A1 (en) * | 2013-03-15 | 2014-09-25 | Massachusetts Institute Of Technology | Use of growth hormone or growth hormone receptor agonists to prevent or treat stress-sensitive psychiatric illness |
| US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
| EP2978766B1 (en) | 2013-03-29 | 2018-12-19 | Ogeda Sa | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| ES2721018T3 (es) | 2013-03-29 | 2019-07-26 | Ogeda S A | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 |
| JP6316932B2 (ja) | 2013-03-29 | 2018-04-25 | オゲダ エス．エー． | 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８位置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、医薬組成物、ＮＫ−３受容体媒介性障害における使用方法 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
| JP6469214B2 (ja) | 2014-09-25 | 2019-02-13 | オゲダ エス．エー． | Ｎ−アシル−（３−置換）−（８−置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジンの新規キラル合成 |
| TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| US10202376B2 (en) | 2014-12-24 | 2019-02-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| HK1256753A1 (zh) | 2015-08-11 | 2019-10-04 | Neomed Institute | 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途 |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017127306A1 (en) | 2016-01-18 | 2017-07-27 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| WO2017127930A1 (en) * | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CN112135825A (zh) | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US12637418B2 (en) | 2019-01-24 | 2026-05-26 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as antagonist of NMDA |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| CN114728962B (zh) | 2019-09-18 | 2025-09-19 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
| CN112608315B (zh) * | 2020-12-14 | 2021-11-30 | 承德医学院 | 三唑并二氮杂卓类化合物及其制备方法及医药用途 |
| EP4384167A1 (en) * | 2021-08-13 | 2024-06-19 | Mpc Therapeutics Sa | [1,2,4]triazolo[4,3-a]pyrimidin-7(8h)-one as mitochondrial pyruvate carrier inhibitors for use in the treatment of cancer |
| CN119998295A (zh) | 2022-06-08 | 2025-05-13 | 因赛特公司 | 作为dgk抑制剂的三环三唑并化合物 |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| CN119997982A (zh) | 2022-09-09 | 2025-05-13 | 迈里克斯制药有限公司 | 包含nmt抑制剂的抗体药物偶联物及其用途 |
| WO2025090941A1 (en) * | 2023-10-27 | 2025-05-01 | The Regents Of The University Of California | Calcium sensing receptor modulators and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3050525A (en) * | 1960-12-14 | 1962-08-21 | John B Bicking | Certain derivatives of s-triazolo [4, 3-a]-pyridine |
| US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
| GB1507462A (en) * | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
| US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
| US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
| AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| AU637316B2 (en) | 1988-01-28 | 1993-05-27 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
| US5216165A (en) * | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
| IT1258790B (it) * | 1992-01-17 | 1996-02-29 | Angelini Francesco Ist Ricerca | Alchil derivati del trazodone |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| WO1995014666A1 (en) | 1993-11-24 | 1995-06-01 | Merck & Co., Inc. | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
| DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
| DE69518075T2 (de) * | 1994-05-24 | 2001-03-22 | F. Hoffmann-La Roche Ag, Basel | Tricyclische dicarbonylderivate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| MY113488A (en) | 1995-01-27 | 2002-03-30 | Novo Nordisk As | Compounds with growth hormone releasing properties |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| EP0766966A3 (en) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| AU715856B2 (en) * | 1995-12-22 | 2000-02-10 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| AUPO864097A0 (en) * | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
| EP1020465B1 (en) | 1997-09-05 | 2008-01-23 | Lead Chemical Co. Ltd. | Stereoisomeric indole compounds, process for the preparation of the same, and use thereof |
| US6114310A (en) | 1998-01-23 | 2000-09-05 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6107324A (en) * | 1998-04-14 | 2000-08-22 | Arena Pharmaceuticals Inc. | 5-HT2A receptor inverse agonists |
| HUP0202648A3 (en) | 1998-06-12 | 2003-02-28 | Sod Conseils Rech Applic | Imidazolyl derivatives, pharmaceutical compositions containing them and their use |
| US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| US6358698B1 (en) * | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
| JP2002531549A (ja) | 1998-12-04 | 2002-09-24 | ブリストル−マイヤーズ スクイブ カンパニー | カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体 |
| US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| US6518292B1 (en) * | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
| US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| US20050148018A1 (en) * | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| KR100879647B1 (ko) * | 2000-03-06 | 2009-01-20 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| NZ526624A (en) * | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| NZ533567A (en) * | 2001-12-28 | 2007-06-29 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| ATE407117T1 (de) * | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| JP2009531390A (ja) * | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
-
2003
- 2003-08-28 MY MYPI20033269A patent/MY139563A/en unknown
- 2003-09-01 TW TW092124121A patent/TWI330185B/zh not_active IP Right Cessation
- 2003-09-01 TW TW099113061A patent/TWI362389B/zh not_active IP Right Cessation
- 2003-09-02 SI SI200332548T patent/SI2570414T1/sl unknown
- 2003-09-02 AU AU2003270065A patent/AU2003270065B2/en not_active Expired
- 2003-09-02 RU RU2005109545/04A patent/RU2382042C2/ru active
- 2003-09-02 EP EP03751958.4A patent/EP1551511B1/en not_active Expired - Lifetime
- 2003-09-02 KR KR1020107028594A patent/KR20110003592A/ko not_active Ceased
- 2003-09-02 SI SI200332585T patent/SI1551511T1/sl unknown
- 2003-09-02 US US10/653,410 patent/US7166596B2/en not_active Expired - Lifetime
- 2003-09-02 PT PT121917579T patent/PT2570414T/pt unknown
- 2003-09-02 RS YU20050186A patent/RS55124B1/sr unknown
- 2003-09-02 ES ES03751958T patent/ES2706578T3/es not_active Expired - Lifetime
- 2003-09-02 JP JP2004534462A patent/JP4658600B2/ja not_active Expired - Lifetime
- 2003-09-02 HU HUE03751958A patent/HUE041936T2/hu unknown
- 2003-09-02 CN CN201010154361A patent/CN101863886A/zh active Pending
- 2003-09-02 ES ES12191757.9T patent/ES2644265T3/es not_active Expired - Lifetime
- 2003-09-02 RS YUP-2005/0186A patent/RS20050186A/sr unknown
- 2003-09-02 DK DK03751958T patent/DK1551511T5/da active
- 2003-09-02 MX MXPA05002301A patent/MXPA05002301A/es active IP Right Grant
- 2003-09-02 BR BR0314024-5A patent/BR0314024A/pt not_active Application Discontinuation
- 2003-09-02 LT LTEP12191757.9T patent/LT2570414T/lt unknown
- 2003-09-02 HU HUE12191757A patent/HUE035498T2/en unknown
- 2003-09-02 HR HRP20050188AA patent/HRP20050188B1/hr not_active IP Right Cessation
- 2003-09-02 PL PL375882A patent/PL219563B1/pl unknown
- 2003-09-02 NZ NZ538166A patent/NZ538166A/en not_active IP Right Cessation
- 2003-09-02 PT PT03751958T patent/PT1551511T/pt unknown
- 2003-09-02 CA CA2496842A patent/CA2496842C/en not_active Expired - Lifetime
- 2003-09-02 LT LTEP03751958.4T patent/LT1551511T/lt unknown
- 2003-09-02 KR KR1020117010024A patent/KR101238041B1/ko not_active Expired - Lifetime
- 2003-09-02 CN CNA038208644A patent/CN1678372A/zh active Pending
- 2003-09-02 EP EP12191757.9A patent/EP2570414B1/en not_active Expired - Lifetime
- 2003-09-02 KR KR1020057003669A patent/KR20050040933A/ko not_active Ceased
- 2003-09-02 DK DK12191757.9T patent/DK2570414T3/en active
- 2003-09-02 GE GEAP20038721A patent/GEP20074019B/en unknown
- 2003-09-02 WO PCT/US2003/027513 patent/WO2004021984A2/en not_active Ceased
- 2003-09-04 AR ARP030103204A patent/AR041143A1/es active IP Right Grant
- 2003-09-04 PE PE2003000897A patent/PE20040997A1/es active IP Right Grant
-
2005
- 2005-02-10 IL IL166802A patent/IL166802A/en active IP Right Grant
- 2005-02-11 NO NO20050748A patent/NO332370B1/no not_active IP Right Cessation
- 2005-02-28 IS IS7719A patent/IS7719A/is unknown
- 2005-11-14 US US11/273,169 patent/US7592354B2/en not_active Expired - Lifetime
- 2005-11-14 US US11/272,898 patent/US7589102B2/en not_active Expired - Lifetime
-
2008
- 2008-06-05 IL IL191960A patent/IL191960A/en active IP Right Grant
-
2009
- 2009-07-22 US US12/507,413 patent/US7910601B2/en not_active Expired - Lifetime
- 2009-09-03 US US12/507,430 patent/US7799801B2/en not_active Expired - Lifetime
-
2010
- 2010-08-09 US US12/852,610 patent/US7977353B2/en not_active Expired - Lifetime
-
2011
- 2011-01-23 IL IL210823A patent/IL210823A/en active IP Right Grant
- 2011-01-23 IL IL210824A patent/IL210824A0/en active IP Right Grant
- 2011-02-17 IL IL211281A patent/IL211281A/en active IP Right Grant
- 2011-05-20 US US13/112,015 patent/US8232291B2/en not_active Expired - Fee Related
-
2012
- 2012-06-11 US US13/493,448 patent/US8557841B2/en not_active Expired - Fee Related
-
2017
- 2017-11-15 CY CY20171101205T patent/CY1120250T1/el unknown
-
2018
- 2018-12-28 CY CY20181101404T patent/CY1121201T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005109545A (ru) | Гетероциклические ароматические соединения | |
| JP2012529486A5 (enExample) | ||
| BRPI0408362A (pt) | combinação de um antagonista de receptor de aldosterona e um agente antidiabético | |
| JP2004534850A5 (enExample) | ||
| JP2003531118A5 (enExample) | ||
| JP2017513882A5 (enExample) | ||
| WO2007050726A3 (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| JP2007502287A5 (enExample) | ||
| RU2007131504A (ru) | Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r) | |
| JP2005513006A5 (enExample) | ||
| EP1621198A3 (en) | Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists | |
| MXPA05010507A (es) | Combinacion de un antagonista del receptor de aldosterona y un agente antiobesidad. | |
| BR9813169A (pt) | Derivados de ciclopenteno úteis como antagonistas do receptor de motilina | |
| BR0214958A (pt) | Derivados de tetraidrocarbazol como ligandos para receptores acoplados à proteìna-g (gpcr) | |
| NO20032261L (no) | Medisinske preparater | |
| EP2279752A3 (en) | Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation | |
| JP2002524460A5 (enExample) | ||
| ES2187771T3 (es) | Uso de la hormona del crecimiento. | |
| JP2001519413A5 (enExample) | ||
| JP2007507472A5 (enExample) | ||
| JP2008543813A5 (enExample) | ||
| EP1159970A3 (en) | A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent | |
| JP2003246730A5 (enExample) | ||
| WO2004080411A3 (en) | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | |
| ATE317700T1 (de) | Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen |